Metabolism Drugs Market

SKU: DMHCIT2967 | Last Updated On: Oct 15 2022 | Available Formats

>Metabolism Drugs Market Expected to reach a high CAGR of 6.54% during the forecast period 2022-2029

Metabolism Drugs Market is segmented By Technology (Separation Tools, High-Performance Liquid Chromatography, Bioinformatic Tools, Databases & Services, Others), By Method (Cancer, Cardiovascular Diseases, Neurological Diseases, Others), By Application (Biomarker and Drug Discovery, Toxicology, Nutrigenomics, Personalized Medicines, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2022-2029

Metabolism Drugs Market Share, Size, Growth Overview

Metabolism Drugs Market is expected to grow at a CAGR of 6.54% during the forecasting period (2022-2029). Metabolism drugs treat metabolic diseases that occur due to a stockpile of proteins, urea, lipids, glycogen, calcium stones, and toxic substances. The improper functioning of metabolism can lead to various metabolic disorders, such as hereditary tyrosinemia, Gaucher disease, Fabry disease, and hereditary orotic aciduria. The rising prevalence of metabolic diseases and the government's support through funding for the study of metabolic disorders are some factors that are expected to propel market growth. Moreover, the research in personalized medicine and the continuous development of advanced analytical tools are further supporting the growth of the market across the globe.

Metabolism Drugs Market Report Statistics



Market CAGR


Segments Covered

By Technology, By Method, By Application and By Region

Report Insights Covered

Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.

Fastest Growing Region

Asia Pacific

Largest Market Share 

North America

To get free sample click here

Metabolism Drugs Market Growth Drivers and Industry Dynamics

Continuous developments in analytical tools are driving the growth of the global market

Mass spectrometry development coupled with chromatography has advanced the reliability and efficiency of metabolomic profiling and shows the key structures in medical fields. The bio-information provided by these technologies enables accurate disease diagnostics and the useful clinical ability to manage diseases at the metabolomic level in absorption. The benefits of high sensitivity, highly accurate, and high throughput metabolomics show substantial capability in disease treatment.

Research conducted by different research institutes and universities has turned to proteomics for developing new biomarkers. The latest research has improved the biomarkers' accuracy as early diagnosis of the diseases enables better treatment. Presently, scientists are focusing on metabolites for detecting the results of the therapy process. In April 2022, Researchers identified a potential new treatment for metabolic syndrome. According to University Hospitals Cleveland Medical Center, they discovered a hormone called asprosin, which stimulates appetite and increases blood glucose levels by acting on the hypothalamus and the liver. Asprosin stimulates appetite by activating key "hunger" neurons of the brain, called AgRP neurons. Asprosin works by binding a protein on the neuron surface called a "receptor."

Metabolism Drugs Market Segmentation Analysis

The high-performance liquid chromatography segment accounted for the highest share in global metabolism drugs market

Mass spectrometers and liquid chromatography have evolved into crucial technology for the field of metabolism drugs. It is used to diagnose colorectal cancer, oral cancer, and hepatocellular carcinoma. Hence, this is established as a new and potential diagnostic approach. The introduction of automated chromatography instruments is expected to further propel the market growth during the forecast period.

Based on the application, the metabolism drugs market has been classified into biomarker and drug discovery, toxicology, nutrigenomics, personalized medicine, etc. The biomarker and drug discovery segment held a significant share in the global metabolism drugs market. There is extensive use of metabolism drugs to apply metabolomics biomarkers and drug discovery to cure chronic diseases such as cancer, neurological disorders, CVDs, etc. Moreover, many small and medium pharmaceutical companies are emerging in the market, intending to develop metabolomics biomarkers to diagnose chronic diseases, fueling the segment's growth over the forecast period. Therefore, it contributes a major share in the growth of the metabolism drugs market globally.

Metabolism Drugs Market Geographical Penetration

North America is the dominating region during the forecast period.

North America dominated the global metabolism drugs market and is expected to retain its position during the forecast period. The US contributed a major share in the North American metabolism drugs market. The region's growth is due to a well-developed healthcare infrastructure and many healthcare research institutes across the region. Moreover, increasing funding in the field of metabolomics is also augmenting the market across the region.

The Asia Pacific is estimated to grow considerably in the metabolism drugs market during the forecast period. Governments of various economies of the region are making efforts to establish R&D centers by foreign-affiliated companies to enhance the metabolism drugs market scenario across the region. Moreover, the rising prevalence of chronic diseases such as cancer and CVDs is fueling the demand for their treatment for novel diagnostic technologies and methods, such as metabolomics biomarkers.

Competitive Landscape:

The metabolism drugs market is highly competitive. The key metabolism drug players contributing to the global market's growth include Agilent Technologies, Bruker Corporation, GE Healthcare, Merck KGaA, Hua Medicine, 3SBio Group, Shanghai Fosun Pharmaceutical(Group Co., Ltd., and Innovent Biologics. Major key players launched a new product in the market to increase their product portfolio. For instance, in January 2022, Agilent Technologies Inc. announced a launch of Agilent Seahorse XF Pro Analyzer with new features like new pharma-oriented workflow solutions incorporating advanced experimental design and analysis tools with more robust and efficient workflows and an optimized user experience; the XF Pro enables operators at any skill level to access the most advanced cellular metabolism analysis technology for understanding cellular fate, fitness, and function. Some major competitors have come together to increase research and development activities. For instance, in June 2021, Washington University collaborated with Agilent and Merck to expand metabolomics research. This collaboration will fast-track the training of next-generation bioanalytical scientists at Washington University, incorporating new workflows combining metabolomics with DMPK analysis to define the mode of action, off-target effects and stratification of results with metabolic biomarkers. In March 2022, Beckman Coulter introduced antipsychotic drug testing to address the unmet clinical need of more than 69 million people living with serious mental conditions.

COVID-19 Impact:

Negative impact on the global metabolism drugs market.

The COVID-19 pandemic has impacted the growth of the metabolism drugs market. The sales of mass spectrometry, chromatography instruments, and other metabolism research instruments have modestly declined, as the prime focus of the research institutes and pharmaceutical companies have diverted to the development of the COVID-19 vaccine. Therefore, the metabolism drugs market is expected to foresee a considerable decline in 2020.

The global metabolism drugs market report would provide an access to approximately 73 market data tables, 57 figures and 170 pages


What is the Growth Rate of the Metabolism Drugs Market?

Throughout the forecast period( 2022-- 2029) it's going to grow by a top CAGR of 6.54%.

What Companies Are Included in the Metabolism Drugs Market?

Agilent Technologies, Bruker Corporation, GE Healthcare, Merck KGaA, Hua Medicine, 3SBio Group, Shanghai Fosun Pharmaceutical(Group Co., Ltd., and Innovent Biologics are the leading market companies with significant market share

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report

20% Discount Applied*

Note*: For "Bundle/Bulk" Subscription of Reports,
please contact: [email protected]

Get your free sample proposal with a single click!